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Summary
Background The diagnosis and staging of lung cancer is an important process that identiﬁ es treatment options and 
guides disease prognosis. We aimed to assess endobronchial ultrasound-guided transbronchial needle aspiration as 
an initial investigation technique for patients with suspected lung cancer.
Methods In this open-label, multicentre, pragmatic, randomised controlled trial, we recruited patients who had 
undergone a CT scan and had suspected stage I to IIIA lung cancer, from six UK centres and randomly assigned 
them to either endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) or conventional 
diagnosis and staging (CDS), for further investigation and staging. If a target node could not be accessed by EBUS-
TBNA, then endoscopic ultrasound-guided ﬁ ne needle aspiration (EUS-FNA) was allowed as an alternative procedure. 
Randomisation was stratiﬁ ed according to the presence of mediastinal lymph nodes measuring 1 cm or more in the 
short axis and by recruiting centre. We used a telephone randomisation method with permuted blocks of four 
generated by a computer. Because of the nature of the intervention, masking of participants and consenting 
investigators was not possible. The primary endpoint was the time-to-treatment decision after completion of the 
diagnostic and staging investigations and analysis was by intention-to-diagnose. This trial is registered with 
ClinicalTrials.gov, number NCT00652769.
Findings Between June 10, 2008, and July 4, 2011, we randomly allocated 133 patients to treatment: 66 to EBUS-TBNA 
and 67 to CDS (one later withdrew consent). Two patients from the EBUS-TBNA group underwent EUS-FNA. The 
median time to treatment decision was shorter with EBUS-TBNA (14 days; 95% CI 14–15) than with CDS (29 days; 
23–35) resulting in a hazard ratio of 1·98, (1·39–2·82, p<0·0001). One patient in each group had a pneumothorax 
from a CT-guided biopsy sample; the patient from the CDS group needed intercostal drainage and was admitted to 
hospital.
Interpretation Transbronchial needle aspiration guided by endobronchial ultrasound should be considered as the 
initial investigation for patients with suspected lung cancer, because it reduces the time to treatment decision 
compared with conventional diagnosis and staging techniques.
Funding UK Medical Research Council.
Copyright © Navani et al. Open Access article distributed under the terms of CC BY.
Introduction
Lung cancer is the most common cause of cancer death 
across the world.1 The clinical staging of non-small-cell 
lung cancer is an important process that identiﬁ es 
treatment options and guides disease prognosis. In 
patients with non-small-cell lung cancer who are ﬁ t for 
surgery and have no evidence of extrathoracic spread, the 
disease status of the mediastinal lymph nodes can be 
used to establish a patient’s suitability for treatment with 
curative intent.2,3
Several invasive and non-invasive techniques are 
available to support the diagnosis and staging of lung 
cancer. Patients with suspected lung cancer undergo a 
CT scan of the lower neck, thorax, and upper abdomen. 
About 50% of patients present with metastatic disease 
that is evident outside the thorax4 and, in these patients, a 
biopsy sample taken from the safest most accessible 
location is recommended. However, in patients with 
solely intrathoracic disease evident on the initial CT scan, 
the diagnostic and staging algorithm is more complex. A 
sample of the primary lesion is generally taken by 
bronchoscopy or CT-guided biopsy before attention turns 
to mediastinal nodal staging. PET-CT is reliable if 
mediastinal lymph nodes that are less than 1 cm in the 
short axis are negative. However, invasive sampling of 
mediastinal lymphadenopathy is recommended when 
lymph nodes are avid for ¹⁸F-ﬂ uorodeoxyglucose 
(¹⁸F-FDG), the tumour is central, there is a PET-positive 
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hilar lymph node, or any mediastinal node is larger than 
1 cm in the short axis (irrespective of ¹⁸F-FDG uptake).5
The diagnosis and staging of patients with intrathoracic 
disease can therefore need several inves tigative 
procedures, including bronchoscopy, radiology-guided 
biopsy sampling, PET-CT, and mediastinoscopy. This 
process often takes several weeks and is a time of great 
anxiety for patients. Additionally, 26% of patients with 
lung cancer report that their health deteriorates while 
waiting for an hospital appointment.6 Further time will 
elapse before a treatment decision has been made which 
could mean that they are unﬁ t for oncological treatments 
by the time a treatment decision has been reached.
The present approach to mediastinal staging of non-
small-cell lung cancer (CT, PET-CT, and mediastinoscopy) 
can result in inaccurate nodal staging in 25% of operable 
patients,7 perhaps because the sensitivity for the detection 
of mediastinal metastases by CT scan is 51%, by PET-CT 
is 74%, and by mediastinoscopy is 78%.5,8
Endobronchial ultrasound-guided transbronchial needle 
aspiration (EBUS-TBNA) is a newer technique that allows 
minimally invasive sampling of all intrathoracic lymph 
nodes adjacent to the bronchial tree. A pooled analysis of 
1299 patients9 with known or suspected non-small-cell 
lung cancer undergoing EBUS-TBNA showed that the 
procedure had a sensitivity of 90% for the detection of 
mediastinal nodal metastases. At the time of the inception 
of our trial in 2007, guidelines4 recommended EBUS-
TBNA as an alternative to mediastinoscopy for patients 
who needed invasive mediastinal sampling after a PET-CT 
scan. Invasive mediastinal sampling is also recommended 
for staging patients with central tumours or patients with 
enlarged or 18F-FDG-avid hilar lymphadenopathy.
Therefore we aimed to investigate whether EBUS-
TBNA could be used as an initial investigation for the 
diagnosis and staging of patients with suspected lung 
cancer because the procedure provides a tissue diagnosis 
and nodal staging in one investigation. Previous studies 
have shown that EBUS-TBNA might represent good 
value for money,10,11 but there is a shortage of information 
about its eﬃ  cacy or cost-eﬀ ectiveness for patients with 
suspected lung cancer. We therefore did the Lung-BOOST 
(BronchOscopic or Oesophageal ultrasound for lung 
cancer diagnosis and STaging) trial—a pragmatic, 
multicentre, randomised controlled trial to test the 
hypothesis that EBUS-TBNA as an initial investigation 
after a staging CT scan would reduce the time to treatment 
decision, and reduce the number of investigations needed 
for the diagnosis and staging of patients with suspected 
lung cancer at no additional cost compared with 
conventional diagnosis and staging (CDS) techniques.
Methods
Study design and participants
We did this randomised controlled trial in six centres in 
the UK (University College London Hospital, Whittington 
Hospital, North Middlesex University Hospital, Princess 
Alexandra Hospital, Barnet General Hospital, and 
Nottingham University Hospital). Patients at these 
centres who were suspected to have stage I to IIIA lung 
cancer on the basis of CT scans of the neck, thorax, and 
upper abdomen were eligible for trial entry. For inclusion 
into the trial, patients had to be aged at least 18 years and 
ﬁ t enough to undergo thoracotomy and lung resection. 
Exclusion criteria were signiﬁ cant concurrent malignant 
disease or any condition or concurrent medicine that 
contraindicated EBUS-TBNA or mediastinoscopy. 
Patients with known extrathoracic malignant disease, 
supraclavicular lymphadenopathy, or pleural eﬀ usion 
were also excluded. The 7th edition of the tumour, node, 
metastasis (TNM) staging system in lung cancer was 
used throughout.12
This investigator-initiated pragmatic trial was approved 
by the UK national research ethics service (reference 07/
H0711/127) and the ethics committees of the six 
participating centres. Patients provided written informed 
consent. 
Randomisation and masking
We randomly assigned participants (1:1) to either 
conventional diagnosis and staging (CDS group) or 
EBUS-TBNA as an initial investigation after a staging CT 
scan followed by further diagnosis and staging 
techniques if needed (EBUS group). We used a telephone 
randomisation method with permuted computer-
generated blocks of four. Randomisation was stratiﬁ ed 
according to the presence of mediastinal lymph nodes 
that measured 1 cm or more in the short axis and by 
recruiting centre. An investigator undertook the 
informed consent process, followed by the telephone 
randomisation process done by research assistants. The 
random allocation sequence was kept in the 
randomisation centre and concealed from participants 
and investigators until the interventions were assigned. 
Because of the nature of the intervention, masking of 
participants and consenting investigators was not 
possible. However, pathologists and radiologists were 
unaware that patients were enrolled into a clinical trial. 
Data were obtained on paper-based case forms and 
entered by an independent clerk onto a secured trial 
database on a dedicated trial computer.
Procedures
Participants allocated to CDS underwent investigations 
as determined by the local multidisciplinary team. We 
suggested an algorithm for CDS in the trial protocol 
based on the most recently available UK National 
Institute of Health and Clinical Excellence guidance 
(2005)13 at the time the trial started (appendix). The trial 
management group agreed that allowing the responsible 
multidisciplinary teams to determine the patients’ 
investigations would provide the best comparator group. 
This allowed the control CDS group to emulate clinical 
practice, giving the trial strong external validity. Patients 
See Online for appendix
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randomly assigned to the EBUS group underwent 
EBUS-TBNA as an initial procedure after a staging CT 
scan (appendix). The procedure was done in the 
outpatient setting with patients given moderate sedation 
with midazolam and fentanyl. We did EBUS-TBNA 
using a dedicated bronchoscope with a linear ultrasound 
probe integrated into the distal end (BF-UC160F-OL8, 
Olympus, Tokyo, Japan, or EB 1970UK, Pentax, Slough, 
UK). A systematic examination of all mediastinal and 
hilar lymph node stations was made. Nodes that we 
suspected were metastatic because of their size or 
location on the CT scan were aspirated with a 22-gauge 
or 21-gauge needle and labelled according to the 
Mountain–Dressler lymph node map. If no enlarged 
nodes were identiﬁ ed, samples were taken via EBUS-
TBNA from the lymph node station that was most likely 
to drain the primary lesion.14 If a target node was 
inaccessible with EBUS-TBNA then endoscopic 
ultrasound-guided ﬁ ne needle aspiration (EUS-FNA) as 
an alternative procedure was allowed. After EBUS-
TBNA, any further investigations needed were 
established by the multidisciplinary team.
Patients were given treatment according to the 
recommendations of the multidisciplinary team. PET-CT 
was recommended for all patients before a decision to 
treat with curative intent. In the absence of symptoms, 
we did not undertake surveillance for brain or bone 
metastases unless radical treatment was planned.
Outcomes
The primary endpoint was the time from ﬁ rst outpatient 
appointment with the respiratory specialist to treatment 
decision by the multidisciplinary team, after completion 
of the diagnosis and staging procedures. We prespeciﬁ ed 
that the primary outcome measure would be analysed in 
the subgroup of patients with non-small-cell lung cancer. 
We prespeciﬁ ed four secondary endpoints: (1) UK 
National Health Service (NHS) costs of diagnosing and 
staging lung cancer, (2) the number of investigations 
and outpatient attendances per patient, (3) the proportion 
of patients diagnosed and staged with one procedure, 
and (4) the number of avoidable thoracotomies. An 
avoidable thoracotomy was deﬁ ned as an open and close 
procedure, unexpected mediastinal nodal metastases 
(pN2/pN3), pT4 or pM1a/b disease, resection of benign 
disease or disease recurrence, or death within 1 year of 
thoracotomy. We also documented the sensitivity, 
negative predictive value, and diagnostic accuracy of 
EBUS-TBNA a priori, and overall survival (post-hoc 
analysis) and complications from the diﬀ erent diagnostic 
and staging techniques.
The incremental cost of EBUS-TBNA as an initial 
investigation compared with CDS was calculated from the 
perspective of the NHS. We included the costs associated 
with all diagnostic and staging investigations. We also 
calculated the costs of treating patients diagnosed with 
lung cancer. Resource use data were obtained prospectively 
in the trial. Unit costs were obtained from NHS reference 
costs,15 NICE 2011 lung cancer guideline,2 and a published 
study;10 these were multiplied by the resource use and 
summed across all resource items.
Statistical analysis
A priori, we expected that 80% of patients would be 
diagnosed and staged with only one investigation in the 
EBUS group, compared with 33% in the CDS group. 
Before the trial began, clinical practice was assessed in a 
retrospective analysis of diagnostic and staging 
procedures in ﬁ ve of the participating centres (data not 
shown). On the basis of this analysis, we estimated that 
patients in the CDS group of the trial would need a 
median time to treatment decision of 30 days, and 
patients in the EBUS group would need a median of 
14 days. A sample size of at least 130 patients was planned 
to give 99% power, assuming a type 1 error of 5%.
Analyses were done for the intention-to-diagnose 
population. The Kaplan-Meier method was used to analyse 
the primary endpoint (time-to-treatment decision). Hazard 
ratios (HRs) were calculated from a Cox model, and did 
Figure 1: Trial proﬁ le
EBUS-TBNA=endobronchial ultrasound-guided transbronchial needle aspiration. 
EUS-FNA=endoscopic ultrasound-guided ﬁ ne needle aspiration. NSCLC=non-small-
cell lung cancer. 
Eligible patients with intrathoracic 
disease only on staging CT scan
Randomisation
133 stratiﬁed by centre and 
mediastinal nodes ≥1 cm
1 patient 
withdrew
67 randomised to conventional 
diagnosis and staging 
66 randomised to EBUS-TBNA 
as initial investigation
Initial investigation
44 bronchoscopy
14 CT guided biopsy
5 conventional TBNA
1 mediastinoscopy
2 PET-CT scan
Initial investigation
64 EBUS-TBNA
2 EUS-FNA
48 PET-CT scan 33 PET-CT scan
Further investigations
15 CT guided biopsy
7 mediastinoscopy
22 other
Further investigations
5 CT guided biopsy
8 mediastinoscopy
1 other
66 included in intention-to- 
diagnose analysis
66 included in intention-to- 
diagnose analysis
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not include adjustment for any baseline factors. We used 
standard deﬁ nitions of sensitivity for the detection of nodal 
metastases. The ﬁ nal diagnosis of nodal staging was 
established in both groups by clinical follow-up of at least 
1 year and pathological changes noted with EBUS-TBNA, 
conventional TBNA, EUS-FNA, mediastinoscopy, or 
dissection of mediastinal lymph nodes.
The Fisher exact test was used to analyse categorical 
data, and unpaired t tests were used to compare groups of 
continuous normally distributed variables. All tests were 
two-sided and 5% was taken as the cutoﬀ  for statistical 
signiﬁ cance. The normal approximation method was used 
to calculate conﬁ dence intervals for the proportions. Final 
statistical analyses were done with STATA (version 10).
This trial is registered on ClinicalTrials.gov, number 
NCT00652769.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, or writing of the report. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between June 10, 2008, and July 4, 2011, we randomly 
assigned 133 patients with suspected lung cancer to the 
CDS group (n=67) and EBUS group (n=66) (ﬁ gure 1). 
One patient (randomly assigned to CDS) declined all 
further investigations and withdrew consent before any 
investigations were done. Both groups were well balanced 
for all major clinical characteristics (table 1).
Lung cancer was diagnosed in 57 (86%) patients in the 
CDS group and 50 (76%) in the EBUS group (p=0·196), 
and clinical staging did not diﬀ er signiﬁ cantly between 
the groups in patients with non-small-cell lung cancer 
(table 2). The benign ﬁ nal diagnoses were pneumonia, 
organising pneumonia, lung abscess, and folded lung.
The median time-to-treatment decision was longer after 
CDS (29 days [95% CI 23–35]), than after EBUS (14 days 
[14–15]; HR 1·98, 95% CI 1·39–2·82, p<0·0001) in the 
intention-to-diagnose population. Therefore patients in 
the EBUS group of the trial were likely to receive a 
treatment decision twice as fast as patients in the CDS 
group (ﬁ gure 2A). A greater proportion of patients had 
diagnosis and staging completed by 14 days in the EBUS 
group than in the CDS group (35 [53%] vs 8 [12%], 
p<0·0001). In the subset of patients with non-small-cell 
lung cancer (ﬁ gure 2B), initial EBUS-TBNA resulted in a 
shorter time-to-treatment decision of 15 days (95% CI 
14–16), compared with 30 days (95% CI 23–34) in the CDS 
group (HR 2·09, 95% CI 1·38–3·15, p=0·0002).
The mean number of investigations per patient, PET 
scans (ﬁ gure 1), and avoidable thoracotomies at 
1 year (table 3). were all signiﬁ cantly lower in the EBUS 
group than in the CDS group, and the number of patients 
diagnosed and staged with one investigation was greater 
(table 3). There were fewer PET scans in the EBUS group 
(33 of 66 [50%]) than in the CDS group (48 of 66 [73%]; 
p=0·002); however, the number of patients having 
treatment with curative intent was similar in each group 
(appendix). 
In the CDS group, 44 (67%) of 66 patients initially 
underwent a bronchoscopy and 29 (44%) had a radiology-
Conventional 
diagnosis and 
staging (n=66)
Endobronchial 
ultrasound-guided 
transbronchial needle 
aspiration (n=66)
Age (years) 68 (IQR 61–73) 71 (IQR 62–78) 
Men 46 (70%) 43 (65%)
Women 20 (30%) 23 (35%)
Ethnic origin
White 59 (89%) 51 (77%)
Asian 2 (3%) 6 (9%)
African 2 (3%) 4 (6%)
Caribbean 2 (3%) 3 (5%)
Other 1 (2%) 2 (3%)
ECOG performance 
status 0 or 1
57 (96%) 60 (92%)
Pack-years smoking history 42 (23·4) 42 (28·1)
FEV1 (L) 1·9 (0·72) 1·9 (0·65)
Clinical nodal staging on initial CT scan
N0 20 (30%) 21 (32%)
N1 9 (14%) 6 (9%)
N2 33 (50%) 34 (51%)
N3 4 (6%) 5 (8%) 
Data are median (range, IQR), n (%), or mean (SD), unless otherwise stated. 
FEV1=forced expiratory volume in 1 s. ECOG=Eastern Cooperative Oncology Group.
Table 1: Baseline characteristics
Conventional 
diagnosis and 
staging (n=66)
Endobronchial 
ultrasound-guided 
transbronchial needle 
aspiration (n=66)
Benign lesion 6 (9%) 14 (21%)
Extrathoracic malignancy 3 (5%) 2 (3%)
Small cell lung cancer 7 (11%) 4 (6%)
Non-small-cell lung cancer 50 (76%) 46 (70%)
Adenocarcinoma 21 (42%) 26 (57%)
Squamous cell 21 (42%) 17 (37%)
Large cell 3 (6%) 1 (2%)
Adenosquamous 2 (4%) 1 (2%)
Not otherwise speciﬁ ed 3 (6%) 1 (2%)
Stage IA/B 11 (22%) 10 (22%)
Stage IIA/B 10 (20%) 6 (13%)
Stage IIIA 20 (40%) 22 (48%)
Stage IIIB 6 (12%) 7 (15%)
Stage IV 3 (6%) 1 (2%)
Data are n (%). Staging is based on the 7th edition of TNM (tumour, node, 
metastasis) staging system for lung cancer.
 Table 2: Final diagnoses and stages of non-small-cell lung cancer
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guided biopsy sample taken; in the EBUS group, 64 (97%) 
of 66 underwent EBUS and two (3%) had EUS-FNA as an 
initial procedure. Five (8%) of 66 patients had a 
subsequent radiology-guided biopsy sample taken 
(appendix). The number of mediastinoscopies did not 
diﬀ er between groups.
In a post-hoc analysis, the median survival of patients 
with non-small-cell lung cancer in the EBUS group of 
503 days (95% CI 312–715) was longer than the median 
survival in the CDS group of 312 days (95% CI 231–488; 
HR 0·60, 0·37–0·98, p=0·0382; ﬁ gure 3). An exploratory 
analysis of lung cancer patients who underwent surgery 
suggested that postoperative survival was better in the 
EBUS group than in the CDS group (appendix).
64 patients in the trial underwent EBUS-TBNA. The 
median size of lymph nodes sampled was 
12 mm (IQR 7–20). The sensitivity of EBUS-TBNA in this 
trial was 92% (95% CI 78–98). The negative predictive 
value of EBUS-TBNA was 90% (72–97) and diagnostic 
accuracy was 95% (86–99). Two patients randomised to 
the EBUS group of the trial underwent EUS-FNA instead 
of EBUS-TBNA, both of whom had station 5 lymph nodes. 
The procedure yielded a diagnosis of malignant disease in 
both patients (one adenocarcinoma and one large cell 
lung cancer). In the CDS group of the study, ﬁ ve patients 
underwent conventional TBNA. Two of these patients had 
a benign ﬁ nal diagnosis, and in one patient conventional 
TBNA provided a diagnosis of squamous cell lung cancer. 
In the remaining two patients undergoing conventional 
TBNA, a negative procedure was followed by a 
mediastinoscopy that showed mediastinal metastases.
One patient in each group had a pneumothorax from a 
CT-guided biopsy sample; the patient in the CDS group 
needed intercostal drainage and was admitted to hospital.
The mean cost per patient for diagnostic and staging 
investigations was £2407 (SD £180·50) in the EBUS 
group and £2348 (192·20) in the CDS group (diﬀ erence 
£59, 95% CI –£463 to £581; appendix). Mean initial 
treatment costs per patient in those diagnosed with lung 
cancer were £4452 (£180·00) and £4261 (£257·90), 
respectively (diﬀ erence £191, 95% CI –447 to 829; 
appendix).
Discussion
The results from our trial suggest that routine use of 
EBUS-TBNA as an initial investigation after a staging CT 
for suspected lung cancer scan results in a faster 
treatment decision, with fewer investigations at no 
signiﬁ cant diﬀ erence in cost, and, in post-hoc analysis, 
seems to improve survival, compared with conventional 
diagnosis and staging methods (panel).
The primary endpoint of our Lung-BOOST trial was 
the time to treatment decision after the test, and the trial 
showed that routine and upfront use of EBUS-TBNA in 
the diagnostic pathway can reduce the median time-to-
treatment decision from 29 days to 14 days. UK 
government initiatives in the NHS Cancer Plan have 
mandated since 2005 that patients receive treatment 
within 62 days of referral, with a maximum of 31 days 
between the decision to treat and the patient receiving 
treatment.16 The time that patients spend undergoing 
diagnostic and staging investigations is a time of great 
anxiety for patients, particularly because the median 
Figure 2: Time to treatment decision in all patients (A) and in those with non-small-cell lung cancer (B)
Kaplan-Meier plots for (A) all patients and (B) patients with non-small-cell lung cancer only undergoing CDS or 
EBUS-TBNA. CDS=conventional diagnosis and staging. NSCLC=non-small-cell lung cancer. EBUS-
TBNA=endobronchial ultrasound-guided transbronchial needle aspiration. HR=hazard ratio.
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Number at risk
CDS
EBUS-TBNA
0
25
50
75
100
A All patients
B NSCLC patients
CDS
EBUS-TBNA
HR 1·98 (95% CI 1·39–2·82), p<0·0001
HR 2·09 (95% CI 1·38–3·15), p=0·0002
Conventional diagnosis 
and staging (n=66)
Endobronchial ultrasound-
guided transbronchial needle 
aspiration (n=66)
p value
Investigations per patient 2·39 (0·78) 1·70 (0·72) <0·0001
Patients diagnosed and staged 
with one investigation
8 (12%) 30 (45%) <0·0001
Avoidable thoracotomies at 1 
year
13 (76%) 5 (29%) 0·035
Data are mean (SD) or n (%).
Table 3: Secondary outcomes
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survival for all patients with lung cancer is poor 
(6·2 months). Importantly, 26% of patients self-report 
that their health deteriorates while awaiting a treatment 
decision.6 Therefore, the primary outcome measure in 
our trial of time-to-treatment decision is of great 
importance to patients and the multidisciplinary teams 
charged with their care. The results from the trial show 
that EBUS-TBNA can provide suﬃ  cient diagnostic and 
staging information in 45% of patients to deﬁ ne the 
treatment plan. PET-CT is recommended for all patients 
unless previous investigations have already shown that 
curative treatment is not an option. Many patients 
diagnosed with N2 disease by EBUS-TBNA will still need 
further investigations, including PET-CT scans if 
combination chemoradiotherapy or surgery are being 
considered. However, in this trial PET-CT was only 
needed for 19% of patients after a positive EBUS-TBNA. 
25 patients with N2 disease in the EBUS group did not 
need a PET scan; of these, four could be candidates for 
chemoradiotherapy and might have a PET scan. Even if 
the wait for this scan took an extra week, this wait would 
not signiﬁ cantly aﬀ ect the median time-to-treatment 
decision. Routine use of EBUS-TBNA was able to reduce 
time-to-treatment decision mainly by reducing the 
number of outpatient appointments and investigations 
(particularly PET-CT scans).
The Lung-BOOST trial recruited patients over 3 years, 
and the rate of accrual was similar to a randomised trial of 
PET-CT in lung cancer staging.17 Since trial inception, 
EBUS-TBNA has become an important investigation for 
patients with lung cancer and is now preferred to 
mediastinoscopy as an initial investigation for nodal 
staging. However, much of the data that lend support to 
its usefulness are based on case series, many of which are 
retrospective and therefore limited by selection bias. The 
randomised design of our trial reduces bias because the 
EBUS-TBNA operators could not choose patients for the 
procedure. Despite not being able to select patients, the 
sensitivity of EBUS-TBNA in the study was high. The 
introduction of EBUS-TBNA in practice has shifted the 
methods of tissue acquisition in patients with lung cancer 
from ﬂ exible bronchoscopy and radiology-guided biopsy 
sampling to EBUS-TBNA. However, to our knowledge, 
this is the ﬁ rst randomised trial to show the eﬀ ect of 
EBUS-TBNA alone on clinical outcomes for patients with 
lung cancer.
The number of mediastinoscopies in the trial was low 
and did not diﬀ er between groups. However, the accuracy 
of preoperative mediastinal node staging was high, 
justifying the approach of the multidisciplinary teams. 
Only one patient in the trial had unexpected pathological 
N2 disease at thoracotomy and had previously undergone 
both EBUS and mediastinoscopy. Previous randomised 
trials of lung cancer staging have used mediastinoscopy 
routinely as part of clinical staging of lung cancer.17,18 For 
example, ASTER18 showed that the combination of EUS 
with EBUS (followed by mediastinoscopy if EBUS or EUS 
was negative) was more eﬀ ective than mediastinoscopy 
alone for diagnosis of mediastinal metastases. Our trial 
substantiates that mediastinoscopy is rarely needed for 
the preoperative staging of non-small-cell lung cancer in 
clinical practice. The results from this trial also suggest 
Figure 3: Overall survival of patients with non-small-cell lung cancer
Survival of patients with non-small-cell lung cancer undergoing CDS or EBUS-TBNA. NSCLC=non-small-cell lung 
cancer. CDS=conventional diagnosis and staging. EBUS-TBNA=endobronchial ultrasound-guided transbronchial 
needle aspiration. HR=hazard ratio.
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Panel: Research in context
Systematic review
Before the trial started, we did a review of the scientiﬁ c 
literature that was subsequently published.14 We compiled the 
information for this review by searching the PubMed and 
Medline databases for English-language articles published 
between Jan 1, 2000, and Jan 1, 2008. Electronic early-release 
publications were also included. The following search terms 
were used: “endobronchial ultrasound”, “endoscopic 
ultrasound”, “lung cancer staging”, “mediastinoscopy”, 
“positron emission tomography”, “PET-CT”, and “mediastinal 
staging”. Full articles were obtained and references were 
checked for additional material, as appropriate. References 
were chosen on the basis of the highest quality clinical 
evidence. No randomised trials of patients with suspected 
lung cancer undergoing EBUS-TBNA only were identiﬁ ed.
Interpretation
EBUS-TBNA is recommended for the mediastinal staging of 
non-small-cell lung cancer and as an alternative to 
mediastinoscopy. The results from our trial show that routine 
use of EBUS-TBNA halved the amount of time between 
testing and treatment decision (compared with conventional 
diagnosis and staging) and should be considered as the initial 
investigation after a CT scan for patients with suspected lung 
cancer and intrathoracic disease at presentation. EBUS-TBNA 
has a high diagnostic sensitivity for detecting nodal 
metastases in patients with lung cancer and could reduce the 
time to treatment decision at no additional cost.
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that EBUS-TBNA could be used as a primary diagnostic 
method in patients with suspected lung cancer rather 
than only as an alternative to mediastinoscopy.
In this trial, EBUS-TBNA was done by systematic 
assessment of all visible lymph node stations. Biopsy 
samples were taken from enlarged lymph nodes and 
lymph nodes that anatomically drained the lung cancer 
primary lesion. This approach achieved a sensitivity of 
92% for nodal staging. Application of PET-CT, with 74% 
sensitivity for nodal staging,5 is therefore not needed 
before EBUS-TBNA. PET-CT, however, remains essential 
for the accurate systemic staging of non-small-cell lung 
cancer before radical treatment.
The management of advanced non-small-cell lung 
cancer now relies on phenotypic sub-classiﬁ cation and 
genotypic analysis of tumours. 41 patients (38%) were 
diagnosed with inoperable lung cancer by EBUS. 
Specimens obtained from EBUS-TBNA are accepted as 
suitable for the personalised approach to the management 
of non-small-cell lung cancer. In a multicentre study,19 
specimens from EBUS-TBNA were suitable for EGFR 
mutation analysis in 90% of cases.
The results of the cost analysis suggested that use of 
EBUS-TBNA as an initial investigation after a CT scan 
was not more expensive than CDS. Because patients in 
the EBUS group of the trial had an earlier treatment 
decision (the primary outcome), we can conclude that 
EBUS-TBNA was more eﬀ ective for the same cost, and 
was therefore cost-eﬀ ective.
There were more avoidable thoracotomies at 1 year in the 
CDS group (13 [76%]) than in the EBUS group (5 [29%]). 
The broader deﬁ nition of avoidable thoracotomy in this 
trial accounts for the high proportion compared with 
unnecessary thoracotomies in previous studies.18
In a post-hoc analysis, survival was higher in patients 
who underwent EBUS-TBNA as part of their diagnostic 
and staging strategy. Further post-hoc analysis suggests 
that this diﬀ erence in survival might be due to superior 
selection (ie, not attributable to health at baseline) of 
candidates for surgery in patients undergoing 
preoperative EBUS-TBNA (appendix). We postulate that 
routine preoperative use of EBUS-TBNA and sampling 
of mediastinal lymph nodes that anatomically drain the 
primary tumour might result in a reﬁ ned population 
undergoing surgery, with improved survival in that 
patient group. Because the use of EBUS-TBNA halved 
the time-to-treatment decision, earlier treatment, when 
the patient is ﬁ tter, could also improve outcome. The 
result of a survival advantage for patients undergoing 
EBUS needs to be replicated.
We recognise that the trial had several limitations. For 
example, the pragmatic nature of the trial meant that a 
consistent diagnostic and staging algorithm was not used 
across all the trial centres. However, the design of the 
study (which was undertaken at two teaching hospitals 
and four general hospitals) gives the results strong 
external validity. Advances in radiotherapy techniques 
during the trial period could mean that more patients 
with mediastinal metastases might now suitable for 
radical treatment and therefore would need PET-CT. In 
this pragmatic trial of patients with suspected lung 
cancer, 19% of the participants had a ﬁ nal diagnosis of 
disorders other than lung cancer, including metastatic 
melanoma and lung abscess. Despite this, the primary 
endpoint was statistically signiﬁ cant for both all patients 
and also those with non-small-cell lung cancer only. 
Finally, in this trial, EBUS-TBNA was undertaken by 
clinicians who were skilled in the procedure—the 
sensitivity of EBUS-TBNA might not be immediately 
reproducible in other centres.
In conclusion, when EBUS-TBNA is used as an initial 
investigation method after a CT scan in patients with 
suspected lung cancer conﬁ ned to the thorax, it can 
provide a diagnosis and accurate nodal stage in one 
investigation. This results in a reduction in the time-to-
treatment decision and might improve survival in 
patients with lung cancer when compared with a 
conventional diagnostic and staging strategy, at no 
additional cost.
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